Cite
HARVARD Citation
Kim, S. et al. (2019). Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Annals of oncology. pp. 788-795. [Online].